Celldex Therapeutics, Inc.

Listed Company

CLDXCIK 0000744218NasdaqLarge AcceleratedIn Vitro & In Vivo Diagnostic SubstancesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.54M

Net Income

$-258.80M

Total Assets

$582.98M

Equity

$527.16M

Shares Out

66.57M

Op. Cash Flow

$-210.90M

Business

Celldex Therapeutics, Inc. is a biopharmaceutical company that researches and develops therapeutic antibodies focused on mast cell biology to treat severe inflammatory, allergic and autoimmune diseases. Its main product candidates include monoclonal antibody barzolvolimab (anti‑KIT) and a next‑generation bispecific platform exemplified by CDX‑622 (anti‑TSLP/anti‑SCF), along with related preclinical and formulation activities. Key business functions comprise discovery and clinical development, manufacturing (internal cGMP capacity and external CDMOs) and business development/partnerships. The company conducts global clinical trials and distributes investigational drug product through clinical sites and contract manufacturers, with formulations designed for clinic and potential at‑home subcutaneous administration.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	2	7	7	2	5
Research and development	245	164	118	82	53
General and administrative	44	39	31	27	20
Litigation settlement related loss	—	—	13	15	—
Total operating expenses	289	202	161	118	76
Operating loss	−287	−195	−155	−115	−71
Investment and other income, net	29	37	13	3	505,000
Net loss	−259	−158	−141	—	—
Basic net loss per common share (in dollars per share)	−3.9	−2.45	−2.92	−2.4	−1.64
Diluted net loss per common share (in dollars per share)	−3.9	−2.45	−2.92	−2.4	−1.64
Shares used in calculating basic net loss per share (in shares)	66	64	48	46,888	42,870
Shares used in calculating diluted net loss per share (in shares)	66	64	48	46,888	42,870
Unrealized gain on marketable securities	312,000	6,000	2	−634,000	−695,000
Comprehensive loss	−258	−158	−139	−113	−71

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	29	28	35	29	39
Marketable securities	490	697	389	276	369
Accounts and other receivables	2	700,000	3	347,000	172,000
Prepaid and other current assets	14	21	5	12	2
Total current assets	535	747	432	318	411
Property and equipment, net	5	4	4	4	4
Operating lease right-of-use assets, net	2	4	3	4	3
Intangible assets	27	27	27	27	27
Other assets	13	10	107,000	104,000	104,000
Total assets	583	792	466	353	445
Accounts payable	1	3	3	3	1
Accrued expenses	47	34	22	13	12
Current portion of operating lease liabilities	2	1	2	1	2
Current portion of long-term liabilities	1	942,000	4	990,000	2
Total current liabilities	51	40	31	19	17
Long-term portion of operating lease liabilities	784,000	2	928,000	3	1
Other long-term liabilities	4	3	4	5	7
Total liabilities	56	45	36	27	25
Commitments and contingent liabilities (Note 15)	—	—	—	—	—
Convertible preferred stock, $.01 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024	—	—	—	—	—
Common stock, $.001 par value; 297,000,000 shares authorized; 66,549,442 and 66,374,549 shares issued and outstanding at December 31, 2025 and 2024, respectively	67,000	66,000	56,000	47,000	47,000
Additional paid-in capital	2,337	2,299	1,823	1,581	1,561
Accumulated other comprehensive income	4	3	3	1	2
Accumulated deficit	−1,814	−1,555	−1,397	−1,256	−1,144
Total stockholders' equity	527	747	429	326	419
Total liabilities and stockholders' equity	583	792	466	353	445

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−259	−158	−141	—	—
Depreciation and amortization	3	3	3	3	3
Amortization and premium of marketable securities, net	−6	−16	−6	844,000	−3
Loss on disposal of assets	12,000	16,000	—	2,000	−24,000
Stock-based compensation expense	36	34	24	16	9
Accounts and other receivables	−1	2	−2	−175,000	2
Prepaid and other current assets	9	−20	6	−10	−2
Other assets	−4	−10	−3,000	—	−5,000
Accounts payable and accrued expenses	11	12	9	3	4
Other liabilities	−753,000	−6	462,000	3	−4
Net cash used in operating activities	−211	−158	−107	−104	−61
Sales and maturities of marketable securities	596	502	321	281	175
Purchases of marketable securities	−385	−790	−425	−189	−390
Acquisition of property and equipment	−3	−2	−2	−2	−1
Net cash provided by (used in) investing activities	209	−290	−106	90	−216
Net proceeds from stock issuances	—	432	216	—	270
Proceeds from issuance of stock from employee benefit plans	2	9	2	4	2
Net cash provided by financing activities	2	441	218	4	272
Net increase (decrease) in cash and cash equivalents	515,000	−6	5	−10	−5
Accrued construction in progress	98,000	27,000	77,000	113,000	289,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro